OBJECTIVE: Left ventricular hypertrophy is a highly prevalent and robust predictor of cardiovascular morbidity and mortality. Existing studies have finely detailed mechanisms involved with its development, yet clinical translation of these findings remains unsatisfactory. We propose an alternative strategy focusing on mechanisms of left ventricular hypertrophy regression rather than its progression and hypothesize that left ventricular hypertrophy regression is associated with a distinct genomic profile. METHODS: Minimally invasive transverse arch banding and debanding (or their respective sham procedures) were performed in C57Bl6 male mice. Left ventricular hypertrophy was assessed physiologically by means of transthoracic echocardiographic analysis, structurally by means of histology, and molecularly by means of real-time polymerase chain reaction. Mouse hearts were genomically analyzed with Agilent (Santa Clara, Calif) mouse 44k developmental gene chips. RESULTS: Compared with control animals, animals banded for 28 days had a robust hypertrophic response, as determined by means of heart weight/body weight ratio, histologic analysis, echocardiographic analysis, and fetal gene expression. These parameters were reversed within 1 week of debanding. Whole-genome arrays on left ventricular tissue revealed 288 genes differentially expressed during progression, 265 genes differentially expressed with regression, and only 23 genes shared by both processes. Signaling-related expression patterns were more prevalent with regression rather than the structure-related patterns associated with left ventricular hypertrophy progression. In addition, regressed hearts showed comparatively more changes in energy metabolism and protein production. CONCLUSIONS: This study demonstrates an effective model for characterizing left ventricular hypertrophy and reveals that regression is genomically distinct from its development. Further examination of these expression profiles will broaden our understanding of left ventricular hypertrophy and provide a novel therapeutic paradigm focused on promoting regression of left ventricular hypertrophy and not just halting its progression.
OBJECTIVE:Left ventricular hypertrophy is a highly prevalent and robust predictor of cardiovascular morbidity and mortality. Existing studies have finely detailed mechanisms involved with its development, yet clinical translation of these findings remains unsatisfactory. We propose an alternative strategy focusing on mechanisms of left ventricular hypertrophy regression rather than its progression and hypothesize that left ventricular hypertrophy regression is associated with a distinct genomic profile. METHODS: Minimally invasive transverse arch banding and debanding (or their respective sham procedures) were performed in C57Bl6 male mice. Left ventricular hypertrophy was assessed physiologically by means of transthoracic echocardiographic analysis, structurally by means of histology, and molecularly by means of real-time polymerase chain reaction. Mouse hearts were genomically analyzed with Agilent (Santa Clara, Calif) mouse 44k developmental gene chips. RESULTS: Compared with control animals, animals banded for 28 days had a robust hypertrophic response, as determined by means of heart weight/body weight ratio, histologic analysis, echocardiographic analysis, and fetal gene expression. These parameters were reversed within 1 week of debanding. Whole-genome arrays on left ventricular tissue revealed 288 genes differentially expressed during progression, 265 genes differentially expressed with regression, and only 23 genes shared by both processes. Signaling-related expression patterns were more prevalent with regression rather than the structure-related patterns associated with left ventricular hypertrophy progression. In addition, regressed hearts showed comparatively more changes in energy metabolism and protein production. CONCLUSIONS: This study demonstrates an effective model for characterizing left ventricular hypertrophy and reveals that regression is genomically distinct from its development. Further examination of these expression profiles will broaden our understanding of left ventricular hypertrophy and provide a novel therapeutic paradigm focused on promoting regression of left ventricular hypertrophy and not just halting its progression.
Authors: Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki Journal: Genome Biol Date: 2003-04-03 Impact factor: 13.583
Authors: Roger A Wagner; Raymond Tabibiazar; Jennifer Powers; Daniel Bernstein; Thomas Quertermous Journal: J Mol Cell Cardiol Date: 2004-12 Impact factor: 5.000
Authors: Janelle R Keys; Emily A Greene; Chris J Cooper; Sathyamangla V Naga Prasad; Howard A Rockman; Walter J Koch Journal: Am J Physiol Heart Circ Physiol Date: 2003-07-17 Impact factor: 4.733
Authors: Kathleen M I Caron; Leighton R James; Hyung-Suk Kim; Josh Knowles; Rick Uhlir; Lan Mao; John R Hagaman; Wayne Cascio; Howard Rockman; Oliver Smithies Journal: Proc Natl Acad Sci U S A Date: 2004-02-20 Impact factor: 11.205
Authors: Stewart H Lecker; R Thomas Jagoe; Alexander Gilbert; Marcelo Gomes; Vickie Baracos; James Bailey; S Russ Price; William E Mitch; Alfred L Goldberg Journal: FASEB J Date: 2004-01 Impact factor: 5.191
Authors: Nikole J Byrne; Jody Levasseur; Miranda M Sung; Grant Masson; Jamie Boisvenue; Martin E Young; Jason R B Dyck Journal: Cardiovasc Res Date: 2016-03-10 Impact factor: 10.787
Authors: Veli K Topkara; Kari T Chambers; Kai-Chien Yang; Huei-Ping Tzeng; Sarah Evans; Carla Weinheimer; Attila Kovacs; Jeffrey Robbins; Philip Barger; Douglas L Mann Journal: JCI Insight Date: 2016-04-06
Authors: Nancy M Andersen; William E Stansfield; Ru-hang Tang; Mauricio Rojas; Cam Patterson; Craig H Selzman Journal: J Surg Res Date: 2012-03-10 Impact factor: 2.192